Ro, originally launched as Roman in 2017 with a focus on men's health conditions like erectile dysfunction and hair loss, has grown into one of the larger direct-to-consumer telehealth platforms in the United States. The company rebranded to Ro as it expanded into dermatology, mental health, fertility, and weight management through its Ro Body program.
Ro Body follows the familiar telehealth model: patients complete an online health assessment, a licensed provider reviews it asynchronously, and if approved, a prescription is issued and medication ships to the patient's door. What distinguishes Ro is its dual-pathway approach: it has historically leaned toward brand-name medications like Wegovy and Ozempic while also expanding into compounded semaglutide and tirzepatide as the market has evolved.
For patients using Ro's compounded pathway, monthly costs generally run $145 to $229 for semaglutide and $199 to $349 for tirzepatide, scaling up as you move through dose tiers. These prices sit toward the higher end of the compounded GLP-1 market, which may reflect Ro's larger multi-vertical corporate structure compared with smaller, more focused platforms.
For patients pursuing brand-name Wegovy or Ozempic through Ro, the picture changes: cash-pay retail for these medications commonly exceeds $1,000/month, but with qualifying commercial insurance and a manufacturer savings card, some patients pay as little as ~$25/month. Ro offers insurance navigation support for this pathway, though success depends heavily on your specific plan, and only about 19% of large employers cover GLP-1s for obesity at all.
The practical effect of dose-tier pricing is that your Ro bill increases over the course of treatment as your provider titrates you upward, which is standard clinical practice for GLP-1s. By the time most patients reach an effective maintenance dose, Ro's compounded tirzepatide pricing can meet or exceed Luma Health's flat $297/month rate, which never changes regardless of dose.
A detailed questionnaire covering medical history, current medications, weight history, BMI, and relevant conditions like type 2 diabetes or cardiovascular disease.
A licensed provider evaluates your submission without a live video visit in most cases, checking against standard clinical eligibility (BMI ≥30, or ≥27 with a weight-related comorbidity).
If approved, you and your provider determine whether you're pursuing the compounded cash-pay pathway or the brand-name insurance pathway, which affects cost and timeline significantly.
Compounded medication ships through Ro's pharmacy network; brand medication is subject to insurance prior authorization and pharmacy dispensing timelines.
Follow-up check-ins track tolerability and dose adjustments, though providers on Ro's platform also cover other health categories, so GLP-1-specific depth can vary by provider.
The side effects patients experience on Ro Body are the side effects of the GLP-1 medications themselves, not the platform. Per FDA prescribing information and the STEP 1 trial, the most common are nausea (reported by up to 44% of semaglutide patients), diarrhea, vomiting, constipation, and reduced appetite, typically strongest during the first 4 to 8 weeks of dose titration. Less common but serious risks include pancreatitis, gallbladder events, and hypoglycemia when combined with insulin or sulfonylureas. Patients with a personal or family history of medullary thyroid carcinoma or MEN 2 should not use GLP-1 medications on any platform.
Years of telehealth infrastructure and a genuine pathway to brand Wegovy or Ozempic for patients with qualifying insurance, including manufacturer savings card support.
Patients who already use Ro for other health categories (dermatology, men's health) may value managing everything in one account.
Compounded tirzepatide climbing to $349/month at top dose tiers is higher than several focused flat-rate competitors at equivalent doses.
Providers evaluating weight-loss patients also cover other verticals on the platform, so GLP-1-specific clinical depth can vary.
Prior authorization, formulary exclusions, and denial risk apply to the brand pathway, independent of Ro's own service quality.
Ro Body is a legitimate, polished platform with real strengths for insured patients seeking brand-name GLP-1s and for those who value having weight loss alongside other health categories in one account. It loses ground on dose-dependent compounded pricing that climbs as you titrate up, and on generalist provider coverage compared with GLP-1-focused platforms. Cash-pay patients paying for compounded tirzepatide at maintenance doses will often find Luma Health's flat $297/month rate a more predictable and, at higher doses, less expensive option.
| Provider | Sema/Month | Tirz/Month | Pharmacy | Commitment |
|---|---|---|---|---|
| Brand Wegovy (cash retail) | ~$1,100–$1,349 | — | Retail chain ✓ | None |
| Ro (compounded, dose-tier) | $145–$229 | $199–$349 | Ro-owned | None |
| ★ Luma Health | $197 flat | $297 flat | VialsRX TX#35264 ✓ | None |
| Henry Meds | ~$89–$145 | ~$179 | Not named | Annual req. |
| Hims | ~$149–$199 | ~$249–$329 | Not named | None |
Henry Meds' annual rate can undercut both Ro and Luma Health at the low end, in exchange for an annual billing commitment and no publicly named pharmacy. Against Ro specifically, Luma Health's flat rate is competitive at starting doses and increasingly favorable as you move to maintenance dosing, where Ro's tiered pricing climbs.
$297/mo flat tirzepatide. $197/mo flat semaglutide. No dose-tier price increases. VialsRX TX#35264. No contracts.
Start With Luma Health →Ro Body is a telehealth weight management service from Ro (formerly Roman) that connects patients with licensed providers who can prescribe GLP-1 medications. It includes an initial health assessment, provider evaluation, and ongoing medication management, with both brand-name and compounded pathways depending on insurance and availability.
Compounded semaglutide generally runs $145–$229/month and compounded tirzepatide $199–$349/month, both scaling up with dose tier. Brand-name Wegovy or Ozempic through insurance can cost as little as ~$25/month with a qualifying plan and manufacturer savings card, or over $1,000/month cash-pay without coverage.
Ro has historically emphasized brand-name pathways and continues to offer them, subject to current supply, insurance coverage, and patient eligibility. Availability can vary, so confirm current options directly with Ro.
Yes. Ro is a well-established company founded in 2017, with licensed providers across multiple states and a substantial patient base. Legitimacy isn't the question most patients should be weighing; cost structure and provider specialization relative to your specific needs are the more useful comparison points.
Ro's compounded tirzepatide has historically been more limited than its semaglutide offering, with availability depending on current pharmacy partnerships and regulatory conditions. Confirm current tirzepatide availability directly with Ro before assuming it's offered in your state.
Yes. Complete Luma Health's intake with your current medication, dose, and treatment timeline. Wasef Health, PC can typically continue you at your current dose rather than restarting titration, provided the switch happens before your Ro supply runs out.
It depends on your dose and insurance status. At starting doses, Ro's compounded pricing can be competitive. At maintenance doses, Ro's tiered pricing often meets or exceeds Luma Health's flat $297/month tirzepatide rate. If you have strong insurance coverage for brand medication, Ro's insurance pathway can beat both.